UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Annual review of biochemistry, ISSN 0066-4154, 6/2016, Volume 85, Issue 1, pp. 375 - 404
cancer therapy | signaling pathways | protein evolution | drug design | p53 family | small-molecule stabilizers | Protein evolution | Signaling pathways | Drug design | Small-molecule stabilizers | P53 family | Cancer therapy | Neoplasms - metabolism | Proto-Oncogene Proteins c-mdm2 - genetics | Antineoplastic Agents, Alkylating - chemical synthesis | Humans | Protein Multimerization | Gene Expression Regulation, Neoplastic | Proto-Oncogene Proteins - chemistry | Molecular Targeted Therapy | Proto-Oncogene Proteins c-mdm2 - chemistry | Tumor Suppressor Protein p53 - genetics | Neoplasms - genetics | Tumor Suppressor Protein p53 - agonists | Drug Design | Nuclear Proteins - genetics | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Proto-Oncogene Proteins c-mdm2 - metabolism | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Protein Structure, Secondary | Signal Transduction | Tumor Suppressor Protein p53 - metabolism | Nuclear Proteins - metabolism | Proto-Oncogene Proteins - genetics | Clinical Trials as Topic | Nuclear Proteins - chemistry | Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Animals | Nuclear Proteins - antagonists & inhibitors | Molecular Docking Simulation | Tumor Suppressor Protein p53 - chemistry | Mutation | Neoplasms - pathology | Transcription factors | Care and treatment | Health aspects | Methods | Cancer | Medical screening | Tumors | Index Medicus
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 07/2017, Volume 10, Issue 1, pp. 133 - 133
MDM2 | Pediatric tumors | Clinical studies | Leukemia | MDMX | Pharmacological inhibitor | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Proto-Oncogene Proteins c-mdm2 - genetics | Protein Interaction Maps - drug effects | para-Aminobenzoates - pharmacology | Humans | Spiro Compounds - therapeutic use | Antineoplastic Agents - therapeutic use | Hematologic Neoplasms - pathology | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Imidazolines - therapeutic use | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Nuclear Proteins - genetics | Child | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Proto-Oncogene Proteins c-mdm2 - metabolism | Hematologic Neoplasms - metabolism | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Tumor Suppressor Protein p53 - metabolism | Imidazolines - pharmacology | Nuclear Proteins - metabolism | Proto-Oncogene Proteins - genetics | Animals | Signal Transduction - drug effects | Nuclear Proteins - antagonists & inhibitors | para-Aminobenzoates - therapeutic use | Hematologic Neoplasms - drug therapy | Indoles - therapeutic use | Hematologic Neoplasms - genetics | Spiro Compounds - pharmacology | Pediatrics | Medical research | Clinical trials | Medicine, Experimental | Development and progression | Tumor proteins | Cancer | Cell proliferation | MDM2 protein | Animal models | Medical innovations | p53 Protein | Genomics | Multiple myeloma | Genomes | Lymphoma | Proteins | Side effects | Chemotherapy | Cell cycle | Mutation | Chromosomes | Regulatory proteins | Tumors | Index Medicus
Journal Article
Cell death and differentiation, ISSN 1350-9047, 01/2010, Volume 17, Issue 1, pp. 93 - 102
MDM2 | cancer therapy | ubiquitylation | p53 | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Neoplasms - therapy | Proto-Oncogene Proteins c-mdm2 - genetics | Ubiquitination | Feedback | Humans | Tumor Suppressor Protein p53 - metabolism | Proto-Oncogene Proteins c-mdm2 - physiology | Proto-Oncogene Proteins c-mdm2 - metabolism | Tumor Suppressor Protein p53 - genetics | Index Medicus
Journal Article